(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/177428 A1

(51) International Patent Classification:
A61K 31/397 (2006.01) *A61P 3/06* (2006.01)
A61K 31/506 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:
PCT/NL2022/050083

(22) International Filing Date:
18 February 2022 (18.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/NL2021/050109
18 February 2021 (18.02.2021) NL

(71) Applicant: **NEWAMSTERDAM PHARMA B.V.** [NL/NL]; Gooimeer 2 35, 1411 DC Naarden (NL).

(72) Inventors: **KASTELEIN, John**; Gooimeer 2 35, 1411 DC Naarden (NL). **DITMARSCH, Marc**; Gooimeer 2 35, 1411 DC Naarden (NL). **DAVIDSON, Michael Harvey**; Gooimeer 2 35, 1411 DC Naarden (NL).

(74) Agent: **NEDERLANDSCH OCTROOIBUREAU**; P.O. Box 29720, 2502 LS The Hague (NL).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** COMBINATION THERAPY OF OBICETRAPIB AND EZETIMIBE FOR USE IN STATIN INTOLERANT PATIENTS SUFFERING FROM HYPERLIPIDEMIA OR MIXED DYSLIPIDAEMIA

Fig. 2



(57) **Abstract:** The present invention relates to a pharmaceutical composition and a therapeutic combination comprising obicetrapib and ezetimibe, which may be used in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia and wherein said subjects are partially or completely intolerant to statins.

WO 2022/177428 A1